CO14. A pivotal study evaluating efficacy and safety of the hedgehog pathway inhibitor (HPI) vismodegib (GDC-0449) in patients with locally advanced (la) or metastatic (m) basal cell carcinoma (BCC)
Year: 2011
Type: conference-abstract
Source: Melanoma Research
Institutions: Mayo Clinic, Mayo Clinic in Arizona, The University of Texas MD Anderson Cancer Center, Stanford Medicine, Stanford University, GZA Ziekenhuizen Campus Sint-Augustinus, University of Colorado Cancer Center, University of Colorado Denver, Sarah Cannon, Northwestern University, University of California, San Francisco, Dana-Farber Cancer Institute, Johns Hopkins University, Genentech, University Hospital Schleswig-Holstein
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W2312451380